Mitogen-activated protein kinase kinase kinase 19 (MAP3K19) (MAP3K19)

Mitogen-activated protein kinase kinase kinase 19 (MAP3K19), also known as YSK4 or RC kinase, is a serine/threonine kinase that has emerged as a key regulator of pro-fibrotic signaling pathways [1, 2]. It is significantly upregulated in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), particularly within alveolar macrophages and bronchial epithelial cells [1, 5]. MAP3K19 functions by modulating the transforming growth factor-beta (TGF-β) signaling cascade; specifically, its activity is required for the nuclear translocation of phosphorylated Smad2 and Smad3, which drive the transcription of fibrotic genes like collagen and fibronectin [2, 25]. Research, primarily led by Vertex Pharmaceuticals, has demonstrated that small-molecule inhibition of MAP3K19 can attenuate lung fibrosis and inflammation in various animal models, including the bleomycin-induced fibrosis model [2, 17]. As a 'dark kinase' with restricted tissue expression, it represents a highly specific therapeutic target aimed at halting the progression of fibroproliferative diseases without the systemic toxicity often associated with broader TGF-β inhibitors [24, 25]. Its role in regulating the cellular response to oxidative stress and inflammation further positions it as a promising target for multi-faceted respiratory conditions [5, 17]. Small-molecule inhibitors of MAP3K19, such as AXP2258, have shown efficacy in reducing myofibroblast activation and extracellular matrix deposition in preclinical studies [18, 21].

Other names

YSK4RC kinaseRCKSps1/Ste20-related kinase homologRegulated in COPD protein kinase

Inhibition of MAP3K19 kinase activity, which prevents TGF-beta-induced Smad2/3 nuclear translocation and subsequent pro-fibrotic gene expression.